Agitation in Alzheimer's Disease Dementia research hub

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia

This study is testing two new medicines, EXV-802 and EXV-801, for people with Alzheimer's disease who experience agitation. It compares these medicines to a dummy pill (placebo) to see if they can help reduce agitation and if they are safe.